At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 10 enrolled
Drug / intervention
letetresgene autoleucel (GSK3377794) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
In Brief
A Phase 1 clinical trial evaluating letetresgene autoleucel (GSK3377794), Cyclophosphamide, and 1 other intervention for Neoplasms. Completed, enrolled 10 participants across 3 sites.
Detailed Summary
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartFeb 2016
Primary CompletionAug 2020
TodayJul 2026
First PostedOct 28, 2015
Enrollment StartFeb 1, 2016
Primary CompletionAug 10, 2020
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 10.7 years ago
Interventions
letetresgene autoleucel (GSK3377794)drug
letetresgene autoleucel (GSK3377794) as an IV infusion.
Cyclophosphamidedrug
Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Fludarabinedrug
Fludarabine will be used as a lymphodepleting chemotherapy.